Chinese pharma company known for pediatric and OTC medicines, including cold/fever remedies for children.
Chinese pharma company known for pediatric and OTC medicines, including cold/fever remedies for children.
Moat: narrow (brand). Recognized consumer brand in China's pediatric OTC medicine segment.
Headquarters: Hubei, China · Employees: 4,137
Size HUBEI JUMPCAN PHARMACEUTICAL (600566.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $4.36B, the 554th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥31.58 on 18 Nov 2026.
Performance Over six months the shares gained 11.8%, against +0.8% for the median peer and -20.0% for the China market (cap-weighted) — 7th highest of 20 in its peer set.
Growth Revenue fell 3.6% over the last twelve months (peer median +10.2%); the operating margin is 31.7% (peer median 15.7%).
Valuation It trades at 16.2× forward earnings against a peer median of 31.1× (4th cheapest of 17).
Price implies For today's price to make sense, revenue must grow about -10% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is -10 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 36.8 points above its cost of capital (5.0% WACC).
Next results Next results expected around 12 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥5.92B | CN¥6.14B | CN¥7.92B | CN¥9.51B | CN¥8.86B |
| Revenue growth | — | -22% | -17% | +7% | — |
| Gross profit | CN¥4.96B | CN¥4.71B | CN¥6.14B | CN¥7.60B | CN¥7.19B |
| EBITDA | n/a | CN¥2.16B | CN¥2.73B | CN¥3.19B | CN¥2.57B |
| Net income | CN¥1.82B | CN¥1.78B | CN¥2.53B | CN¥2.82B | CN¥2.17B |
| Free cash flow | CN¥1.47B | CN¥1.29B | CN¥2.09B | CN¥3.24B | CN¥2.44B |
| Capital expenditure | CN¥260M | CN¥95.9M | CN¥174M | CN¥302M | CN¥244M |
| Total debt | CN¥1.44B | CN¥912M | CN¥1.16B | CN¥1.58B | CN¥733M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| HUBEI JUMPCAN PHARMACEUTICAL 600566.SS | $4.36B | +12% | -4% | 32% | 16.2× | -9.9% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | $6.59B | +6% | +4% | 14% | 13.2× | -6.2% |
| China Resources Jiangzhong Pharmaceutical 600750.SS | $2.27B | +4% | -10% | 24% | 16.5× | -1.9% |
| Guangzhou Baiyunshan Pharmaceutical 600332.SS | $4.45B | -13% | +1% | 3% | 12.9× | -0.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600566.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +18.3% | -2.9% | 3rd highest of 21 |
| 6-month return | +11.8% | +0.8% | 7th highest of 20 |
| Distance from 52-week high | -0.2% | -32.7% | highest of 21 |
| Revenue growth (TTM) | -3.6% | +10.2% | 3rd lowest of 19 |
| Operating margin | 31.7% | 15.7% | 5th highest of 19 |
| Forward P/E | 16.2× | 31.1× | 4th cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | -9.9% | 7.3% | least demanding of 17 |
| Growth delivered (Del g) | +0.3% | +10.9% | lowest of 17 |
| Hurdle (Req g minus delivered) | -10.1 pp | -3.7 pp | 6th least demanding of 17 |
| ROIC minus cost of capital | +36.8 pp | +4.9 pp | 2nd highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| HUBEI JUMPCAN PHARMACEUTICAL 600566.SS | China | $4.36B | +12% | -4% | 32% | 16.2× | -9.9% | +0.3% |
| Camurus CAMX.ST | Sweden | $4.36B | +36% | +3% | 38% | 45.1× | 7.9% | +46.5% |
| Ajanta Pharma AJANTPHARM.NS | India | $4.38B | +1% | +25% | 25% | 31.7× | 23.8% | +13.8% |
| Shenzhen Salubris Pharmaceuticals 002294.SZ | China | $4.31B | -24% | +14% | 11% | 35.4× | 12.4% | +9.7% |
| Guangzhou Baiyunshan Pharmaceutical 600332.SS | China | $4.45B | -13% | +1% | 3% | 12.9× | -0.7% | +4.7% |
| Ionis Pharmaceuticals IONS | United States | $4.56B | -64% | -1% | -59% | n/a | n/a | n/a |
| Santen Pharmaceutical 4536.T | Japan | $4.14B | +10% | +2% | 16% | 16.7× | -5.0% | +3.2% |
| Yuhan 000100.KS | South Korea | $4.11B | -10% | +8% | 6% | 40.4× | n/a | n/a |
| Emcure Pharmaceuticals EMCURE.NS | India | $4.74B | +37% | +21% | 16% | 33.6× | 15.9% | +12.7% |
| Definium Therapeutics DFTX | United States | $3.99B | +40% | n/a | n/a | n/a | n/a | n/a |
| GlaxoSmithKline Pharmaceuticals GLAXO.NS | India | $4.79B | +10% | +12% | 33% | 37.3× | 26.4% | +5.5% |
| HanmiPharm 128940.KS | South Korea | $3.95B | -2% | +14% | 16% | 15.0× | 4.7% | +7.5% |
| Travere Therapeutics TVTX | United States | $4.82B | +16% | +49% | -3% | 17.1× | 17.3% | +19.9% |
| Erasca ERAS | United States | $4.83B | +24% | n/a | n/a | n/a | n/a | n/a |
| Novast Laboratories 301569.SZ | China | $3.92B | n/a | +3% | 27% | n/a | 57.4% | +3.1% |
| Humanwell Healthcare (Group) 600079.SS | China | $4.87B | +11% | +2% | 15% | 13.8× | -8.8% | +3.0% |
| Beijing TongRenTang 600085.SS | China | $4.91B | -12% | -17% | 8% | 28.7× | 1.7% | +6.2% |
| Sunshine Guojian Pharmaceutical (Shanghai) 688336.SS | China | $3.81B | -38% | +227% | 74% | 39.9× | 0.9% | +45.1% |
| IPCA Laboratories IPCALAB.NS | India | $5.03B | +12% | +12% | 18% | 31.1× | 16.5% | +12.2% |
| PTC Therapeutics PTCT | United States | $5.03B | -15% | -35% | 22% | 31.2× | 6.6% | +35.4% |
| SKBP 326030.KS | South Korea | $5.03B | -16% | +37% | 38% | 21.5× | -4.4% | +93.6% |